论文部分内容阅读
Recently,glucagon-like peptide-1(GLP-1)receptor agonists have become a cornerstone for the treatment of obese patients with type 2 diabetes(T2D),exhibiting favorable effects on the cardiovascular outcome.In T2D,impaired GLP-1 secretion/function is observe